Alder BioPharmaceuticals Priced, Nasdaq: ALDR
Developing antibodies to prevent migraine and treat rheumatoid arthritis.
Industry: Health Care
First Day Return: +0.3%
ALDR
Developing antibodies to prevent migraine and treat rheumatoid arthritis.
| IPO Data | |
|---|---|
| IPO Date | 05/07/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $80 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Bothell, WA, United States |
| Founded | 2002 |
| Employees at IPO | 77 |
| Website www.alderbio.com | |
IPO News for Alder BioPharmaceuticals
Alder BioPharmaceuticals (ALDR) Performance
